<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Asthma Allergy</journal-id><journal-id journal-id-type="iso-abbrev">J Asthma Allergy</journal-id><journal-id journal-id-type="publisher-id">Journal of Asthma and Allergy</journal-id><journal-title-group><journal-title>Journal of Asthma and Allergy</journal-title></journal-title-group><issn pub-type="epub">1178-6965</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22923997</article-id><article-id pub-id-type="pmc">3422814</article-id><article-id pub-id-type="doi">10.2147/JAA.S31402</article-id><article-id pub-id-type="publisher-id">jaa-5-033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Long-term use of doxycycline can improve chronic asthma and possibly remodeling: the result of a pilot observation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bhattacharyya</surname><given-names>Parthasarathi</given-names></name><xref ref-type="corresp" rid="c1-jaa-5-033"/></contrib><contrib contrib-type="author"><name><surname>Paul</surname><given-names>Rantu</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bhattacharjee</surname><given-names>Partha</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ghosh</surname><given-names>Arko</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dey</surname><given-names>Ratna</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ghosh</surname><given-names>Malabika</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Madan</given-names></name></contrib><aff id="af1-jaa-5-033">Institute of Pulmocare and Research, CB 16, Salt Lake, Sector 1, Kolkata, India</aff></contrib-group><author-notes><corresp id="c1-jaa-5-033">Correspondence: Parthasarathi Bhattacharyya, Institute of Pulmocare and Research, CB 16, Salt Lake, Sector 1, Kolkata-700064, India, Fax +91 332 358 0424, Email <email>parthachest@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>08</day><month>8</month><year>2012</year></pub-date><volume>5</volume><fpage>33</fpage><lpage>37</lpage><permissions><copyright-statement>&#x000a9; 2012 Bhattacharyya et al, publisher and licensee Dove Medical Press Ltd.</copyright-statement><copyright-year>2012</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Progressive loss of lung function and reversibility characterize chronic asthma. The conventional therapy is targeted to control the disease without targeting the loss of lung function or reversibility. In a prospective real-world observation of long-term use of add-on doxycycline as a matrix-metalloproteinase inhibitor, we documented significant improvement in lung function with possible reversal of remodeling.</p><sec><title>Background</title><p>Chronic asthma shows progressive decline in lung function with reduction or even loss of reversibility secondary to remodeling. A set of endopeptidase enzymes known as matrix metalloproteinases are intimately related to the pathogenesis of asthma and remodeling. The inhibition of matrix metalloproteinases is recognized as a prospective way of treating asthma and its corresponding structural remodeling.</p></sec><sec><title>Methods</title><p>In a randomized, prospective, real-world study, we have observed the change in lung function (spirometry) with an add-on of long-term doxycycline to standard asthma therapy as per the Global Initiative for Asthma guidelines in a small asthmatic population. The change in terms of forced expiratory volume (FEV<sub>1</sub>), forced vital capacity (FVC), percent of FEV<sub>1</sub> (FEV<sub>1</sub>%), and forced expiratory flow (FEF<sub>25&#x02013;75</sub>) were noted following variable duration of doxycycline therapy.</p></sec><sec><title>Results</title><p>There has been a global improvement in all the parameters in all the six patients suggesting improvement in obstruction, and reduction in air trapping following a treatment of add-on doxycycline for a mean duration of 162.83 &#x000b1; 83.07 days. Of the changes seen, the post bronchodilator FEV<sub>1</sub>, the FVC, and the FEF<sub>25&#x02013;75</sub> showed significant improvements with the <italic>P</italic>-value set at 0.004, 0.054, and 0.031, respectively. There was also evidence of the reversal of remodeling from the improvement in the FEV<sub>1</sub>/FVC ratio. Moreover there was a greater than expected improvement of pre-bronchodilator FEV<sub>1</sub> after treatment that far surpassed the initial post-bronchodialator FEV<sub>1</sub> value. Even after such a change, there were presences of some reversibility suggesting room for further improvement.</p></sec><sec><title>Conclusion</title><p>The results suggest significant improvements in the obstructive parameters used to evaluate asthma, with possible reversal of remodeling evident in chronic asthmatics when treated with doxycycline in addition to standard therapies. This observation needs further scientific validation.</p></sec></abstract><kwd-group><kwd>chronic asthma</kwd><kwd>doxycycline</kwd><kwd>FEV<sub>1</sub></kwd><kwd>FEV<sub>1</sub>/FVC</kwd><kwd>matrix metalliproteinase</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Asthma is a disease of airway inflammation and airway hyper-responsiveness<xref ref-type="bibr" rid="b1-jaa-5-033">1</xref> with progressive narrowing of the airways due to both reversible and irreversible functional and structural changes; the apparently irreversible changes in chronic asthma have been denoted as remodeling given that they result in reduction in lung function and vary in terms of the degree of reversibility.<xref ref-type="bibr" rid="b2-jaa-5-033">2</xref> Assessment of airways by high-resolution computerized tomography (CT) of the chest can have a good correlation to the pathological measures of remodeling.<xref ref-type="bibr" rid="b3-jaa-5-033">3</xref> Of late, the forced expiratory volume (FEV<sub>1</sub>) forced vital capacity (FVC) ratio (FEV<sub>1</sub>/FVC) has also been detected as a surrogate marker of remodeling that correlates well with the airway changes assessed by CT scan.<xref ref-type="bibr" rid="b4-jaa-5-033">4</xref> The pathophysiology of asthma inflammation and airway remodeling has been marked by different microstructural changes including abnormal extracellular matrix turnover and fibrosis<xref ref-type="bibr" rid="b5-jaa-5-033">5</xref>,<xref ref-type="bibr" rid="b6-jaa-5-033">6</xref> through the participation of an enzyme system called matrix metalloproteinase (MMPs) and its tissue inhibitor.<xref ref-type="bibr" rid="b7-jaa-5-033">7</xref>&#x02013;<xref ref-type="bibr" rid="b9-jaa-5-033">9</xref> Since modulation of the process by inhibition of MMPs may be beneficial to the asthmatics, we used doxycycline on a long-term basis in an open, prospective, real-world observation. We conducted this pilot work to see the effect of this antibiotic for its additional property of matrix metalloproteinase inhibition<xref ref-type="bibr" rid="b10-jaa-5-033">10</xref>&#x02013;<xref ref-type="bibr" rid="b12-jaa-5-033">12</xref> and suppression of immunoglobulin-E (IgE)<xref ref-type="bibr" rid="b13-jaa-5-033">13</xref> alongside the use of standard asthma medications.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="subjects"><title>Inclusion of patients</title><p>We selected chronic asthmatics from the outpatient department of the institute who had long standing history of asthma symptoms with documented airflow limitation and significant reversibility (200 mL and 12%) using spirometry in compliance with the American Thoracic Society guideline.<xref ref-type="bibr" rid="b14-jaa-5-033">14</xref> The subjects were incorporated in a real-world observation protocol (approved by the Institutional Ethics Committee) upon signing the written informed consent form to undergo treatment with doxycycline on a long-term basis. Patients younger than 13 years and older than 75 years of age, those unwilling to undergo the study, and those having previous history of doxycycline intolerance or history of exacerbation within the preceding 6 weeks were excluded. Since it was a real world observation, we kept the study in tandem with the practicing style of the physician and the logistics of the real world. All the patients were informed of the need to (a) have repeated spirometry examinations; (b) attend regular follow-up visits; and (c) report the side effects (experienced or suspected), if any, apart from the need to continue doxycycline as an add-on therapy on top of optimal asthma treatments as per the Global Initiative for Asthma guidelines.<xref ref-type="bibr" rid="b15-jaa-5-033">15</xref> All the patients were on inhaled long-acting beta agonists plus inhaled corticosteroids with inhaled reliever short-acting &#x003b2;<sub>2</sub> agonist prior to randomization so as to stabilize symptoms for at least 6 weeks. Patients were informed about the possible side effects of doxycycline and were instructed to consume the medicine at least 1 hour after eating. The offered dose of doxycycline was 100 mg twice daily and 100 mg once daily for patients with body weight over 40 kg or less than 40 kg, respectively. Ranitidine was co-prescribed universally to lessen the chance of gastrointestinal intolerance. The baseline spirometry data were preserved and the follow up spirometry data were incorporated for statistical analysis as soon as they were available. We looked for changes in both the pre- (initial) and post-bronchodilator values of spirometric variables across the FEV<sub>1</sub>, FVC, ratio of FEV<sub>1</sub>/FVC, and FEF<sub>25&#x02013;75</sub> for documentation of improvement, and changes in the FEV<sub>1</sub>/FVC for marking the improvement of remodeling according to the observations outlined by Chae et al.<xref ref-type="bibr" rid="b4-jaa-5-033">4</xref></p><p>Statistical calculations were done on these spirometric variables using two-tailed paired <italic>t</italic>-tests, and significance was noted with a <italic>P</italic>-value &#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Of the 24 patients being prescribed add-on doxycycline, a total of six patients (three males and three females, mean age of 47.0 &#x000b1; 14.6 years) were included for data analysis. Their follow-ups were noted during the period from March 15, 2011 to November 03, 2011. Each patient showed an improvement in their asthma symptoms and exhibited reversibility, according to spirometry results. From the rest of the 18 patients, 10 did not perform repeat spirometry before or during the period of data collection. A total of four patients consumed the medicine inconsistently, two had stopped the therapy after a few days, and one had started the drug only recently. In another patient, the drug was stopped for subsequent diagnosis of tuberculosis.</p><p>The mean duration of add-on doxycycline between the baseline and posttreatment spirometric assessment was noted as 162.83 &#x000b1; 83.07 days and the changes in the spirometric variables are displayed in <xref ref-type="table" rid="t1-jaa-5-033">Table 1</xref>. There was a global improvement across all the parameters; however, the change in the post-bronchodilator FEV<sub>1</sub> was the most significant (<italic>P</italic> = 0.004). The other significant changes noted were post-bronchodilator FVC (<italic>P</italic> = 0.054), and both pre-and post-bronchodilator FEF<sub>25&#x02013;75</sub> (<italic>P</italic> = 0.023 and <italic>P</italic> = 0.031, respectively).</p><p>When the pre- (baseline) and posttreatment values were plotted on a duration scale, all the variables showed progressive improvement with time. However, the post-bronchodilator values exhibited more significant improvements compared to the pre-bronchodilator values for FEV<sub>1</sub>, FVC, percentage of forced exhaled volume (FEV<sub>1</sub>%), and FEF<sub>25&#x02013;75</sub> (displayed in <xref ref-type="fig" rid="f1-jaa-5-033">Figure 1A to D</xref>). No adverse effects of doxycycline were reported by the patients.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Asthma is a global problem with a huge health care burden,<xref ref-type="bibr" rid="b16-jaa-5-033">16</xref> and remodeling of asthma is a universal phenomenon. The loss of lung function has been found to be accelerated in asthma despite therapy.<xref ref-type="bibr" rid="b17-jaa-5-033">17</xref>,<xref ref-type="bibr" rid="b18-jaa-5-033">18</xref> So far, the treatment of asthma consists essentially of inhaled bronchodilators and inhaled corticosteroids with oral bronchodilators and anti-inflammatory agents used in certain situations as per the recommendation of treatment guidelines.<xref ref-type="bibr" rid="b15-jaa-5-033">15</xref> Asthma therapy has been targeted to achieve symptom &#x02018;control&#x02019; and there has been no option available to treat the accelerated loss of lung function from remodeling.<xref ref-type="bibr" rid="b15-jaa-5-033">15</xref> Clinically, remodeling implies a progressive loss of lung function and reversibility, while pathologically it signifies an array of micro-structural changes that include the deposition and degradation of the extracellular matrix and fibrosis.<xref ref-type="bibr" rid="b2-jaa-5-033">2</xref> Abnormal deposition of the extracellular matrix has been observed in the submucosal and adventitial areas in both the large and small airways.<xref ref-type="bibr" rid="b5-jaa-5-033">5</xref>,<xref ref-type="bibr" rid="b6-jaa-5-033">6</xref>,<xref ref-type="bibr" rid="b19-jaa-5-033">19</xref>,<xref ref-type="bibr" rid="b20-jaa-5-033">20</xref></p><p>Matrix metalloproteinases, a class of Zn-endopeptidase, and their tissue inhibitors (TIMPs) play a very significant role in the process. Several MMPS are found up-regulated in asthma; of these, MMP-9 has been found in higher quantities in the sputum, bronchoalveolar lavage fluid, and serum of asthmatics,<xref ref-type="bibr" rid="b7-jaa-5-033">7</xref>&#x02013;<xref ref-type="bibr" rid="b9-jaa-5-033">9</xref> and is also found to be elevated in several different situations such as asthma exacerbation,<xref ref-type="bibr" rid="b21-jaa-5-033">21</xref> occupational asthma,<xref ref-type="bibr" rid="b22-jaa-5-033">22</xref> and nocturnal asthma.<xref ref-type="bibr" rid="b23-jaa-5-033">23</xref> Similarly, the tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) has been found to be elevated in asthmatics.<xref ref-type="bibr" rid="b7-jaa-5-033">7</xref> The MMP/ TIMP balance is regarded as important in the development of allergy-induced asthma since it is reduced by the pulmonary administration of TIMP-1 or TIMP-2.<xref ref-type="bibr" rid="b24-jaa-5-033">24</xref> In animal models, different MMP inhibitors are found to reduce airway inflammation<xref ref-type="bibr" rid="b24-jaa-5-033">24</xref> and bronchial hyperreactivity.<xref ref-type="bibr" rid="b25-jaa-5-033">25</xref></p><p>Both early and late reactions in asthma have been found to be reduced in sheep models when MMP inhibitors are used, and thus MMP inhibition may be a prospective therapeutic target in asthmatics.<xref ref-type="bibr" rid="b26-jaa-5-033">26</xref>,<xref ref-type="bibr" rid="b27-jaa-5-033">27</xref> We have tried to exploit this concept in a few cases of chronic asthma with the long-term use of a known MMP inhibitor, doxycycline.<xref ref-type="bibr" rid="b10-jaa-5-033">10</xref>,<xref ref-type="bibr" rid="b11-jaa-5-033">11</xref>,<xref ref-type="bibr" rid="b12-jaa-5-033">12</xref> Such use of doxycycline has been approved by the United States Food and Drug Administration for the treatment of periodontal disease,<xref ref-type="bibr" rid="b28-jaa-5-033">28</xref> and the long-term use of doxycycline has been documented in several other indications with few toxicities noted.<xref ref-type="bibr" rid="b29-jaa-5-033">29</xref>&#x02013;<xref ref-type="bibr" rid="b32-jaa-5-033">32</xref></p><p>Incidentally, doxycycline is also able to suppress IgE, and this property can also be exploited for the treatment of asthma.<xref ref-type="bibr" rid="b13-jaa-5-033">13</xref> Daoud et al have documented the use of minocycline among people with asthma, and they examined the effects of this drug across a number of spirometric parameters of lung function as related to IgE suppression.<xref ref-type="bibr" rid="b33-jaa-5-033">33</xref>,<xref ref-type="bibr" rid="b34-jaa-5-033">34</xref> Doxycycline was found to successfully reduce the airway inflammation and hyper-responsiveness in murine model of Toluene di-isocyanate induced asthma.<xref ref-type="bibr" rid="b35-jaa-5-033">35</xref> Thus, we conclude that doxycycline, by virtue of its MMP inhibitory and IgE suppressive properties, can be a useful adjunct in the management of asthma.</p><p>In our observations, we noted significant improvements across measures of obstruction (FEV<sub>1</sub>), and also across the surrogate marker of remodeling FEV<sub>1</sub>/FVC.<xref ref-type="bibr" rid="b3-jaa-5-033">3</xref> The changes in FEF<sub>25&#x02013;75</sub> and FEV<sub>1</sub> suggest that the observed changes took place both in medium and small-sized airways. Given that the improvement exceeded the expected post-bronchodilator value and yet maintaining some reversibility, it suggests some structural changes that may have resulted from the use of the intervention to the benefit of the patients. Such supranormal improvement in the posttreatment spirometry with demonstration of existence of some reversibility suggests the scope of further improvement. Our results clearly exceeded our expectations, and this implies that the so-called remodeling is not necessarily a fixed structural change.</p><p>Our observation may be the first of its kind to show a change in the natural history of asthma by pharmacotherapy. Subsequent research should try to address how long this therapy can be continued and how far the natural history of asthma can be changed. It is not possible to speak about the side effects of doxycycline in this observation given that our sample size included a small number of patients. In addition, the chances of gastrointestinal toxicities and the reflux related to the administration of this drug were, perhaps, lessened by the universal use of ranitidine. A good prospective, randomized, double blind study with a much larger sample population might be able to address these questions.</p><p>Despite several weaknesses in the current study (ie, small sample size, real-world observation, no control group, no histological proof, and no high-resolution CT assessment of remodeling), our observations warrant attention and further validation.</p></sec></body><back><fn-group><fn id="fn1-jaa-5-033"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-jaa-5-033"><label>1</label><element-citation publication-type="journal"><collab>Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma</collab><article-title>This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986</article-title><source>Am Rev Respir Dis</source><year>1987</year><volume>136</volume><fpage>225</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">3605835</pub-id></element-citation></ref><ref id="b2-jaa-5-033"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>JA</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Chupp</surname><given-names>G</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name></person-group><article-title>Airway remodeling in asthma</article-title><source>J Clin Invest</source><year>1999</year><volume>104</volume><issue>8</issue><fpage>1001</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">10525034</pub-id></element-citation></ref><ref id="b3-jaa-5-033"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aysola</surname><given-names>RS</given-names></name><name><surname>Hoffman</surname><given-names>EA</given-names></name><name><surname>Gierada</surname><given-names>D</given-names></name><etal/></person-group><article-title>Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology</article-title><source>Chest</source><year>2008</year><volume>134</volume><issue>6</issue><fpage>1183</fpage><lpage>1191</lpage><pub-id pub-id-type="pmid">18641116</pub-id></element-citation></ref><ref id="b4-jaa-5-033"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chae</surname><given-names>EJ</given-names></name><name><surname>Kim</surname><given-names>TB</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Airway measurement for airway remodeling defined by post-bronchodilator FEV1/FVC in asthma: investigation using inspiration-expiration computed tomography</article-title><source>Allergy Asthma Immunol Res</source><year>2011</year><volume>3</volume><issue>2</issue><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">21461250</pub-id></element-citation></ref><ref id="b5-jaa-5-033"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauad</surname><given-names>T</given-names></name><name><surname>Xavier</surname><given-names>AC</given-names></name><name><surname>Saldiva</surname><given-names>PH</given-names></name><name><surname>Dolhnikoff</surname><given-names>M</given-names></name></person-group><article-title>Elastosis and fragmentation of fibers of the elastic system in fatal asthma</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>160</volume><issue>3</issue><fpage>968</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">10471626</pub-id></element-citation></ref><ref id="b6-jaa-5-033"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parameswaran</surname><given-names>K</given-names></name><name><surname>Willems-Widyastuti</surname><given-names>A</given-names></name><name><surname>Alagappan</surname><given-names>VK</given-names></name><name><surname>Radford</surname><given-names>K</given-names></name><name><surname>Kranenburg</surname><given-names>AR</given-names></name><name><surname>Sharma</surname><given-names>HS</given-names></name></person-group><article-title>Role of extracellular matrix and its regulators in human airway smooth muscle biology</article-title><source>Cell Biochem Biophys</source><year>2006</year><volume>449</volume><issue>1</issue><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">16456242</pub-id></element-citation></ref><ref id="b7-jaa-5-033"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cataldo</surname><given-names>D</given-names></name><name><surname>Munaut</surname><given-names>C</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name><etal/></person-group><article-title>MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease</article-title><source>Int Arch Allergy Immunol</source><year>2000</year><volume>123</volume><issue>3</issue><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">11112863</pub-id></element-citation></ref><ref id="b8-jaa-5-033"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mautino</surname><given-names>G</given-names></name><name><surname>Henriquet</surname><given-names>C</given-names></name><name><surname>Gougat</surname><given-names>C</given-names></name><etal/></person-group><article-title>Increased expression of tissue inhibitor of metalloproteinase-1 and loss of correlation with matrix metalloproteinase-9 by macrophages in asthma</article-title><source>Lab Invest</source><year>1999</year><volume>79</volume><issue>1</issue><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">9952109</pub-id></element-citation></ref><ref id="b9-jaa-5-033"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vignola</surname><given-names>AM</given-names></name><name><surname>Riccobono</surname><given-names>L</given-names></name><name><surname>Mirabella</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sputum metalloproteinase-9/ tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>158</volume><issue>6</issue><fpage>1945</fpage><lpage>1950</lpage><pub-id pub-id-type="pmid">9847290</pub-id></element-citation></ref><ref id="b10-jaa-5-033"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pires</surname><given-names>PW</given-names></name><name><surname>Rogers</surname><given-names>CT</given-names></name><name><surname>McClain</surname><given-names>JL</given-names></name><name><surname>Garver</surname><given-names>HS</given-names></name><name><surname>Fink</surname><given-names>GD</given-names></name><name><surname>Dorrance</surname><given-names>AM</given-names></name></person-group><article-title>Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2011</year><volume>301</volume><issue>1</issue><fpage>H87</fpage><lpage>H97</lpage><pub-id pub-id-type="pmid">21551278</pub-id></element-citation></ref><ref id="b11-jaa-5-033"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>LL</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Doxycycline attenuates acrolein-induced mucin production, in part by inhibiting MMP-9</article-title><source>Eur J Pharmacol</source><year>2011</year><volume>650</volume><issue>1</issue><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">21036164</pub-id></element-citation></ref><ref id="b12-jaa-5-033"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaito</surname><given-names>K</given-names></name><name><surname>Urayama</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>G</given-names></name></person-group><article-title>Doxycycline treatment in a model of early abdominal aortic aneurysm</article-title><source>Surg Today</source><year>2003</year><volume>33</volume><issue>6</issue><fpage>426</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">12768368</pub-id></element-citation></ref><ref id="b13-jaa-5-033"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith-Norowitz</surname><given-names>TA</given-names></name><name><surname>Bluth</surname><given-names>MH</given-names></name><name><surname>Drew</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effect of minocycline and doxycycline on IgE responses</article-title><source>Ann Allergy Asthma Immunol</source><year>2002</year><volume>89</volume><issue>2</issue><fpage>172</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">12197574</pub-id></element-citation></ref><ref id="b14-jaa-5-033"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrino</surname><given-names>R</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name><name><surname>Crapo</surname><given-names>RO</given-names></name><etal/></person-group><article-title>Interpretive strategies for lung function tests</article-title><source>Eur Respir J</source><year>2005</year><volume>26</volume><issue>5</issue><fpage>948</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">16264058</pub-id></element-citation></ref><ref id="b15-jaa-5-033"><label>15</label><element-citation publication-type="book"><collab>http://www.ginasthma.org</collab><comment>[homepage on the Internet]</comment><source>Pocket guide for asthma management and prevention</source><publisher-name>Global Initiative for Asthma (GINA)</publisher-name><comment>updated 2011. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ginasthma.org/guidelines-pocket-guide-for-asthma-management.html">http://www.ginasthma.org/guidelines-pocket-guide-for-asthma-management.html</ext-link></comment><date-in-citation>Accessed 18 June, 2012</date-in-citation></element-citation></ref><ref id="b16-jaa-5-033"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masoli</surname><given-names>M</given-names></name><name><surname>Fabian</surname><given-names>D</given-names></name><name><surname>Holt</surname><given-names>S</given-names></name><name><surname>Beasley</surname><given-names>R</given-names></name></person-group><collab>for Global Initiative for Asthma (GINA) Program</collab><article-title>The global burden of asthma: executive summary of the GINA Dissemination Committee report</article-title><source>Allergy</source><year>2004</year><volume>59</volume><issue>5</issue><fpage>469</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">15080825</pub-id></element-citation></ref><ref id="b17-jaa-5-033"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peat</surname><given-names>JK</given-names></name><name><surname>Woolcock</surname><given-names>AJ</given-names></name><name><surname>Cullen</surname><given-names>K</given-names></name></person-group><article-title>Rate of decline of lung function in subjects with asthma</article-title><source>Eur J Respir Dis</source><year>1987</year><volume>70</volume><issue>3</issue><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">3569449</pub-id></element-citation></ref><ref id="b18-jaa-5-033"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>P</given-names></name><name><surname>Parner</surname><given-names>J</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Schnohr</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>G</given-names></name></person-group><article-title>A 15-year follow-up study of ventilatory function in adults with asthma</article-title><source>N Engl J Med</source><year>1998</year><volume>339</volume><issue>17</issue><fpage>1194</fpage><lpage>1200</lpage><pub-id pub-id-type="pmid">9780339</pub-id></element-citation></ref><ref id="b19-jaa-5-033"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakir</surname><given-names>J</given-names></name><name><surname>Shannon</surname><given-names>J</given-names></name><name><surname>Molet</surname><given-names>S</given-names></name><etal/></person-group><article-title>Airway remodeling associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>111</volume><issue>6</issue><fpage>1293</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">12789232</pub-id></element-citation></ref><ref id="b20-jaa-5-033"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Medeiros Matsushita</surname><given-names>M</given-names></name><name><surname>da Silva</surname><given-names>LF</given-names></name><name><surname>dos Santos</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Airway proteoglycans are differentially altered in fatal asthma</article-title><source>J Pathol</source><year>2005</year><volume>207</volume><issue>1</issue><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">16041692</pub-id></element-citation></ref><ref id="b21-jaa-5-033"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Lee</surname><given-names>HB</given-names></name><name><surname>Rhee</surname><given-names>YK</given-names></name><name><surname>Song</surname><given-names>CH</given-names></name></person-group><article-title>The involvement of matrix metalloproteinase- 9 in airway inflammation of patients with acute asthma</article-title><source>Clin Exp Allergy</source><year>2001</year><volume>31</volume><issue>10</issue><fpage>1623</fpage><lpage>1630</lpage><pub-id pub-id-type="pmid">11678864</pub-id></element-citation></ref><ref id="b22-jaa-5-033"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palikhe</surname><given-names>NS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name></person-group><article-title>Biomarkers predicting isocyanateinduced asthma</article-title><source>Allergy Asthma Immunol Res</source><year>2011</year><volume>3</volume><issue>1</issue><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">21217921</pub-id></element-citation></ref><ref id="b23-jaa-5-033"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>DN</given-names></name><name><surname>Chu</surname><given-names>HW</given-names></name><name><surname>Martin</surname><given-names>RJ</given-names></name><name><surname>Kraft</surname><given-names>M</given-names></name></person-group><article-title>Increased matrix metalloproteinase-9 with elastolysis in nocturnal asthma</article-title><source>Ann Allergy Asthma Immunol</source><year>2003</year><volume>90</volume><issue>1</issue><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">12546341</pub-id></element-citation></ref><ref id="b24-jaa-5-033"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumagai</surname><given-names>K</given-names></name><name><surname>Ohno</surname><given-names>I</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><issue>7</issue><fpage>4212</fpage><lpage>4219</lpage><pub-id pub-id-type="pmid">10201949</pub-id></element-citation></ref><ref id="b25-jaa-5-033"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>PS</given-names></name></person-group><article-title>The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity</article-title><source>Toxicol Appl Pharmacol</source><year>2005</year><volume>205</volume><issue>2</issue><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">15893540</pub-id></element-citation></ref><ref id="b26-jaa-5-033"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name><surname>Sypek</surname><given-names>J</given-names></name><name><surname>Tavendale</surname><given-names>R</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase- 12 is a therapeutic target for asthma in children and young adults</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>126</volume><issue>1</issue><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">20546881</pub-id></element-citation></ref><ref id="b27-jaa-5-033"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma</article-title><source>J Med Chem</source><year>2009</year><volume>52</volume><issue>17</issue><fpage>5408</fpage><lpage>5419</lpage><pub-id pub-id-type="pmid">19725580</pub-id></element-citation></ref><ref id="b28-jaa-5-033"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golub</surname><given-names>LM</given-names></name><name><surname>Lee</surname><given-names>HM</given-names></name><name><surname>Ryan</surname><given-names>ME</given-names></name><name><surname>Giannobile</surname><given-names>WV</given-names></name><name><surname>Payne</surname><given-names>J</given-names></name><name><surname>Sorsa</surname><given-names>T</given-names></name></person-group><article-title>Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms</article-title><source>Adv Dent Res</source><year>1998</year><volume>12</volume><issue>2</issue><fpage>12</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">9972117</pub-id></element-citation></ref><ref id="b29-jaa-5-033"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>P</given-names></name><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Acharyya Ghosh</surname><given-names>D</given-names></name><name><surname>Chowdhury</surname><given-names>SR</given-names></name><name><surname>Bardhan</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name></person-group><article-title>Treatment of probable idiopathic pulmonary fibrosis with long term doxycycline, a matrix metalloproteinase inhibitor</article-title><source>Indian Journal of Chest Disease and Allied Sciences</source><year>2007</year><volume>49</volume><issue>3</issue><fpage>180</fpage></element-citation></ref><ref id="b30-jaa-5-033"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>P</given-names></name><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Bardhan</surname><given-names>S</given-names></name><etal/></person-group><article-title>The role of long-term doxycycline in patients of idiopathic pulmonaryfibrosis: The results of an open prospective trial</article-title><source>Lung India</source><year>2009</year><volume>26</volume><issue>3</issue><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">20442842</pub-id></element-citation></ref><ref id="b31-jaa-5-033"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>PN</given-names></name><name><surname>Chaulet</surname><given-names>JF</given-names></name><name><surname>Brockman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><issue>4</issue><fpage>1622</fpage><lpage>1625</lpage><pub-id pub-id-type="pmid">15793155</pub-id></element-citation></ref><ref id="b32-jaa-5-033"><label>32</label><element-citation publication-type="book"><collab>http://www.hpa.org.uk</collab><comment>[homepage on the Internet]</comment><source>Malaria</source><publisher-loc>London</publisher-loc><publisher-name>Health Protection Agency</publisher-name><year>2012</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.hpa.org.uk/infections/topics_az/malaria/">http://www.hpa.org.uk/infections/topics_az/malaria/</ext-link></comment><date-in-citation>Accessed 18 June, 2012</date-in-citation></element-citation></ref><ref id="b33-jaa-5-033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daoud</surname><given-names>A</given-names></name><name><surname>Gloria</surname><given-names>CJ</given-names></name><name><surname>Taningco</surname><given-names>G</given-names></name><etal/></person-group><article-title>Minocycline treatment results in reduced oral steroid requirements in adult asthma</article-title><source>Allergy Asthma Proc</source><year>2008</year><volume>29</volume><issue>3</issue><fpage>286</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">18534087</pub-id></element-citation></ref><ref id="b34-jaa-5-033"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joks</surname><given-names>R</given-names></name><name><surname>Smith-Norowitz</surname><given-names>T</given-names></name><name><surname>Nowakowski</surname><given-names>M</given-names></name><name><surname>Bluth</surname><given-names>MH</given-names></name><name><surname>Durkin</surname><given-names>HG</given-names></name></person-group><article-title>Tetracycline-mediated IgE isotype-specific suppression of ongoing human and murine IgE responses in vivo and murine memory IgE responses induced in vitro</article-title><source>Int Immunol</source><year>2010</year><volume>22</volume><issue>4</issue><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">20181654</pub-id></element-citation></ref><ref id="b35-jaa-5-033"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Jin</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name></person-group><article-title>Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma</article-title><source>J Allergy Clin Immunol</source><year>2004</year><volume>113</volume><issue>5</issue><fpage>902</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">15131573</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-jaa-5-033" position="float"><label>Figure 1</label><caption><p>Changes in FEV<sub>1</sub>, FVC, FEV<sub>1</sub>%, and FEF<sub>25&#x02013;75</sub> as a function of initial and after use of add-on doxycycline treatment. (<bold>A</bold>&#x02013;<bold>D</bold>) denote the changes in different parameters (FEV<sub>1</sub>, FVC, FEV<sub>1</sub>%, FEF<sub>25&#x02013;75</sub>, respectively), expressed as a function of time in both their initial (dotted line) and after use of add-on doxycycline treatment (continuous line) values.</p><p><bold>Abbreviations:</bold> FEV<sub>1</sub>, forced expiratory volume; L, liters; FVC, forced vital capacity; FEV<sub>1</sub>%, percentage of forced expiratory volume; FEF<sub>25&#x02013;75</sub> (L/s), patient&#x02019;s exhaled flow (liters per second).</p></caption><graphic xlink:href="jaa-5-033f1"/></fig><table-wrap id="t1-jaa-5-033" position="float"><label>Table 1</label><caption><p>Changes in spirometric variables in response to treatment of add-on doxycycline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Before treatment pre-BD</th><th align="left" valign="top" rowspan="1" colspan="1">After treatment pre-BD</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" valign="top" rowspan="1" colspan="1">Before treatment post-BD</th><th align="left" valign="top" rowspan="1" colspan="1">After treatment post-BD</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="left" valign="top" rowspan="1">
<hr/></th><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="left" valign="top" rowspan="1">
<hr/></th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Mean &#x000b1; SD</th><th align="left" valign="top" rowspan="1" colspan="1">Mean &#x000b1; SD</th><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Mean &#x000b1; SD</th><th align="left" valign="top" rowspan="1" colspan="1">Mean &#x000b1; SD</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub> (L)</td><td align="center" valign="top" rowspan="1" colspan="1">1.12 &#x000b1; 0.40</td><td align="center" valign="top" rowspan="1" colspan="1">1.38 &#x000b1; 0.29</td><td align="left" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">1.30 &#x000b1; 0.43</td><td align="center" valign="top" rowspan="1" colspan="1">1.61 &#x000b1; 0.34</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.004</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC (L)</td><td align="center" valign="top" rowspan="1" colspan="1">1.97 &#x000b1; 0.60</td><td align="center" valign="top" rowspan="1" colspan="1">2.13 &#x000b1; 0.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.256</td><td align="center" valign="top" rowspan="1" colspan="1">2.12 &#x000b1; 0.63</td><td align="center" valign="top" rowspan="1" colspan="1">2.44 &#x000b1; 0.56</td><td align="left" valign="top" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>%</td><td align="center" valign="top" rowspan="1" colspan="1">56.98 &#x000b1; 11.73</td><td align="center" valign="top" rowspan="1" colspan="1">65.13 &#x000b1; 6.61</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.028</bold></td><td align="center" valign="top" rowspan="1" colspan="1">61.83 &#x000b1; 13.33</td><td align="center" valign="top" rowspan="1" colspan="1">66.55 &#x000b1; 6.84</td><td align="left" valign="top" rowspan="1" colspan="1">0.227</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEF<sub>25&#x02013;75</sub> (L/s)</td><td align="center" valign="top" rowspan="1" colspan="1">0.68 &#x000b1; 0.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 &#x000b1; 0.21</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.023</bold></td><td align="center" valign="top" rowspan="1" colspan="1">0.86 &#x000b1; 0.31</td><td align="center" valign="top" rowspan="1" colspan="1">1.06 &#x000b1; 0.23</td><td align="left" valign="top" rowspan="1" colspan="1"><bold>0.031</bold></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-jaa-5-033"><p><bold>Notes:</bold> The table shows the change in the different spirometric variables (FEV<sub>1</sub>, FVC, FEV<sub>1</sub>%, and FEF<sub>25&#x02013;75</sub>), in terms of both pre- and post-bronchodilator values from treatment of add-on doxycycline. The significant changes (<italic>P</italic> &#x0003e; 0.05) are marked in bold.</p></fn><fn id="tfn2-jaa-5-033"><p><bold>Abbreviations:</bold> BD, bronchodilator; <italic>P</italic>, probability level; SD, standard deviation; FEV<sub>1</sub>, forced expiratory volume; L, liters; FVC, forced vital capacity; FEV<sub>1</sub>%, percentage of forced expiratory flow; FEF<sub>25&#x02013;75</sub> (L/s), patient&#x02019;s exhaled volume (liters per second).</p></fn></table-wrap-foot></table-wrap></floats-group></article>